Goldman Sachs’s Adient ADNT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
– Sell
-110
Closed -$4K – 5193
2018
Q3
$4K Hold
110
– – ﹤0.01% 5514
2018
Q2
$5K Hold
110
– – ﹤0.01% 5580
2018
Q1
$7K Hold
110
– – ﹤0.01% 5777
2017
Q4
$9K Sell
110
-5,000
-98% -$403K ﹤0.01% 6213
2017
Q3
$429K Sell
5,110
-13,200
-72% -$936K ﹤0.01% 5202
2017
Q2
$1.2M Buy
18,310
+7,570
+70% +$515K ﹤0.01% 4296
2017
Q1
$780K Buy
10,740
+9,200
+597% +$604K ﹤0.01% 4610
2016
Q4
$90K Buy
+1,540
New +$81.3K ﹤0.01% 6187

Other funds holding ADNT

Goldman Sachs's ADNT Position: Q2 2026 in Review

Goldman Sachs reduced its Adient (ADNT) stake by 35% in Q2 2026, selling an estimated $16.7M and leaving 1,432,916 shares worth $26.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2383.

Goldman Sachs first reported a position in ADNT in Q4 2016 and has held it in 39 quarters since. The position peaked at $112M in Q2 2021. 313 funds tracked by Wall St. Rank hold ADNT as of Q2 2026.

  • Goldman Sachs held 1,432,916 shares of Adient worth $26.3M as of Q2 2026.
  • Goldman Sachs sold 780,794 Adient shares in Q2 2026, an estimated $16.7M.
  • Adient made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2383 holding.
  • Goldman Sachs first reported a position in Adient in Q4 2016 and has held it in 39 quarters since.
  • Goldman Sachs's Adient position peaked at $112M in Q2 2021.
  • 313 funds tracked by Wall St. Rank held Adient as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.